Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, multi-site Phase II trial of pembrolizumab in combination
with pemetrexed and cisplatin or carboplatin as neo-adjuvant therapy followed by surgery and
adjuvant pembrolizumab in patients affected by resectable stage I-IIIa chemonaïve
epithelioid/biphasic pleural mesothelioma.